Navigation Links
ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
Date:2/14/2011

CHICAGO, Feb. 14, 2011 /PRNewswire/ -- Zoledronic acid (sold by Novartis as Zometa, Aclasta, and Reclast) is used to treat Osteoporosis, Tumor Metastasis, and Paget's Disease with sales of $2 billion a year.(1)  It is associated with side effects such as post-dose syndrome and osteonecrosis of the jaw.  A new patented method from Dr. Ketan Desai enables the administration of Zoledronic acid in combination with another drug that relieves the side effects.

(Logo:  http://photos.prnewswire.com/prnh/20100614/CG20517LOGO)

This patented method will be auctioned off at ICAP Ocean Tomo's Spring 2011 Live IP Auction on March 31, 2011 in New York City. Key Characteristics of MethodThe patents disclose the following:


  • Method enables administration of zoledronic acid in a novel combination.
  • Method results in decreased side effects.
  • Can be administered though different methods: oral supply, inhalation, muscle injection, or veindrip.
  • Market OverviewThese patents may be of interest in the following areas:


  • The global market for pain management pharmaceuticals and devices amounted to $19.1 billion in 2008 and is expect to reach $32.8 billion in 2013.(2)
  • These patents would be of interest to: pharmaceutical companies, drug manufacturers, healthcare service providers, and biomedical research.
  • To learn more about the assets available for sale in this portfolio: Contact Dean Becker of ICAP Ocean Tomo at Dean.Becker@us.icap.comAbout ICAP Ocean Tomo LLCICAP Ocean Tomo is the intellectual property brokerage division of ICAP and the world's premier patent auction firm.

    About ICAPICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to www.icap.com.

    (1) http://www.thepharmaletter.com/file/100554/novartis-zometa-fails-to-meet-ph-iii-primary-endpoint-in-early-breast-cancer-stalling-this-indication-but-afinitor-looks-good.html

    (2) http://www.bccresearch.com/report/HLC026C.html


    '/>"/>

    SOURCE ICAP Ocean Tomo
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cutting Edge Nanotech Patents for Displays, Lighting, X-ray, Medical Imaging, and Diagnostics Available for Sale by ICAP Ocean Tomo
    2. ICAP Ocean Tomo to Auction 7 Exclusive Licenses from Lawrence Livermore National Laboratory at Fall Auction November 11th in Napa, California
    3. Skin Lesion Identification System to Auction on November 11th at ICAP Ocean Tomos Fall 2010 Live IP Auction
    4. ICAP Ocean Tomo Offers for Sale IP Portfolio of Active Implants for Electromagnetic Bone and Tissue Regeneration in Orthopedics, Trauma, and Wound Care
    5. ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.
    6. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
    7. Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing
    8. Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
    9. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
    10. Dynatronics Announces Fiscal Second Quarter Results
    11. K-V Pharmaceutical Company Announces Completion of a $32 Million Private Placement of Class A Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/27/2017)... Ind., July 27, 2017  Zimmer Biomet Holdings, Inc. ... quarter ended June 30, 2017.  The Company reported second ... 1.1% over the prior year period, and an increase ... 240 basis points of contribution from the LDR Holding ... the second quarter of 2016, or 0.3% on a ...
    (Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
    (Date:7/26/2017)... July 26, 2017 E.I. Medical Imaging (EIMI) ... Bimini SharkLab to custom design the worlds first ultrasound system to ... in their native habitat. In preparation for a piece produced ... Shark Week, Dr. Guttridge approached EIMI with the idea ... directly to hammerhead sharks underwater. ...
    Breaking Medicine Technology:
    (Date:7/27/2017)... ... 27, 2017 , ... Somnoware, a leading provider of digital ... solution to its healthcare management platform. This solution provides physicians with remote scoring ... of scoring in the cloud is on par with doing it on a ...
    (Date:7/27/2017)... (PRWEB) , ... July 27, 2017 , ... The Los Angeles leg of the US ... 2017 at 7:00pm and will be held at the Clive Davis Theater inside the Grammy ... Camo Jacket, chronicles the story of the iconic Welsh rock musician, Mike Peters (of The ...
    (Date:7/27/2017)... ... July 27, 2017 , ... Team Novo Nordisk, the ... to the men’s pro squad as a stagiaire for the remainder of the 2017 ... debut on July 31st at the Tour of Utah. , “Every season we are ...
    (Date:7/26/2017)... ... July 26, 2017 , ... Capillus, LLC has announced the redesign of ... new Flexible Fitting Design offers a more comfortable, adaptable fit and is available for ... improvements to the home-use laser therapy caps intended to improve both user experience and ...
    (Date:7/26/2017)... ... ... A major challenge many labs face is a direct result from a ... dry cycle are a few common challenges that can overcome when following best practices. ... and advancements in laboratory freeze dryers that will improve quality and reduce the time ...
    Breaking Medicine News(10 mins):